Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
03/29 SANOFI : and Regeneron Announce FDA Approval of Dupixent (dupilumab), the First ..
03/29 VIVUS : to Regain Commercial Rights for Stendra from Sanofi
03/29 SANOFI : and Regeneron Announce FDA Approval of Dupixent (dupilumab), the First ..
03/29 SANOFI : Regeneron and Sanofi land the big one, winning FDA approval for their m..
03/28 SANOFI : Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXE..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28 SANOFI : and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First..
03/28 SANOFI : and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First..
03/28 SANOFI : Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), th..
More news
Sector news : Pharmaceuticals - NEC
11:07aDJOXFORD BIOMEDICA : Hails U.S. Regulatory Boost for Leukemia Treatment
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/29 FDA Approves Regeneron Pharmaceuticals (REGN) And Sanofi's (SNY) Dupixent - S..
03/29 Sanofi Needs Dupixent To Meet Lofty Expectations
03/29 Sanofi advancing toward sale of European generics unit
03/28 FDA OKs Regeneron and Sanofi's dermatitis med Dupixent
03/27 My Favorite Biotech Takeover Play
Advertisement
Financials (€)
Sales 2017 36 401 M
EBIT 2017 9 391 M
Net income 2017 5 584 M
Debt 2017 4 512 M
Yield 2017 3,53%
P/E ratio 2017 18,64
P/E ratio 2018 17,62
EV / Sales 2017 3,12x
EV / Sales 2018 2,99x
Capitalization 109 189 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 82,0 €
Spread / Average Target -3,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI9.90%117 436
JOHNSON & JOHNSON9.07%338 645
ROCHE HOLDING LTD.8.81%221 440
PFIZER INC.5.70%204 439
NOVARTIS AG-0.47%197 239
MERCK & CO., INC.8.10%174 728
More Results